Intravenous rESP administered every other week was noninferior to rhEPO for treating anemia in hemodialysis patients with chronic renal failure, demonstrating comparable safety profiles.
ApolloDialDb v2.0 provides a massive, multinational real-world database of over 850,000 dialysis patients to characterize practice patterns, emulate trials, and inform care models.
Absolute Event Rate: 0% vs 0%
Conclusion:In this 36-week, phase III trial comparing maintenance therapy with rESP administered intravenously every other week with rhEPO administered intravenously one to three times weekly, rESP was noninferior to rhEPO for the treatment of anemia in patients with chronic renal failure undergoing hemodialysis, with comparable safety profiles.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Jiao et al. (Wed,) reported a other. Intravenous rESP administered every other week was noninferior to rhEPO for treating anemia in hemodialysis patients with chronic renal failure, demonstrating comparable safety profiles.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: